The role of diagnostics in the management of antibiotic resistance



Anna Zorzet
Brussels
23 May 2011



The consequences of not having fast and reliable diagnostic tools

No diagnostic tools



Blind (empirical) use of antibiotics



Antibiotics over and mis-use






Increasing resistance Treatment failure



Survival of patients depends on time to <u>effective</u> antibiotics






Clinical challenges

- Prescribe antibiotic only when bacterial infection is confirmed
- Use the right and efficient antibiotic

Is the patient infected?




React
Action on Antibiotic Resistance

Clinical challenges

- Prescribe antibiotic only when bacterial infection is confirmed
- Use the right and efficient antibiotic

Is the patient infected?



Use the **right** antibiotic (AB)

= Efficient, narrow spectrum,
 limited adverse effects, cheap
 Keep the AB choice → maintain the AB efficiency and Control resistance



Additional areas in need of diagnostics

- Surveillance
 - Trends and magnitude of resistance
- Collecting burden data
 - Estimating costs
- Clinical trials (new antibiotics)
 - Finding correct patient groups



COUNCIL OF THE EUROPEAN UNION



Antibiotic Resistance

Council Conclusions on innovative incentives for effective antibiotics

2980th EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS Council meeting

Brussels, 1 December 2009

- explore ways to promote further public-private partnerships between industry, academia, non-profit organisations and the healthcare system to facilitate research into new antibiotics, strategies for use of currently available antibiotics and <u>diagnostic</u> methods;
- ensure the development and use of integrated strategies to diminish the development and spread of antibiotic resistance as well as healthcare-associated infections and their consequences, encourage healthcare institutions to have structures in place as well as ensuring effective coordination of programmes focusing on <u>diagnosis</u>, antibiotic stewardship and infection control;

Current usage of diagnostic tools is low!

- Industrialized countries
 - 2% of health expenses but influence 60–70% of health decisions
- Developing countries
 - Spending on diagnostics ranges from negligible to 6%

Peeling and Mabey 2010. Point-of-care tests for diagnosing infections in the developing world Lewin Group 2005. The value of diagnostics: innovation, adoption and diffusion into health care.




The standard method has not changed for 50 years!

Day 1: Obtaining a pure culture.
Species determination by biochemical testing



Day 2: Testing for antibiotic resistance





The standard method has not changed for 50 years!

Day 1: Obtaining a pure culture.


Species determination by biochemical testing

Day 2: Testing for antibiodic resistance





Survival of patients depends on time to <u>effective</u> antibiotics





Slow and ancient diagnostics are compromising patient safety





What can we do about it?

